Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
57.88
-0.35 (-0.60%)
At close: Nov 20, 2024, 4:00 PM
57.80
-0.08 (-0.14%)
Pre-market: Nov 21, 2024, 5:10 AM EST
BMY Revenue
Bristol-Myers Squibb Company had revenue of $11.89B in the quarter ending September 30, 2024, with 8.44% growth. This brings the company's revenue in the last twelve months to $47.44B, up 5.56% year-over-year. In the year 2023, Bristol-Myers Squibb Company had annual revenue of $45.01B, down -2.50%.
Revenue (ttm)
$47.44B
Revenue Growth
+5.56%
P/S Ratio
2.47
Revenue / Employee
$1,391,056
Employees
34,100
Market Cap
117.39B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | 26.15B | 3.58B | 15.89% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Cigna Group | 229.75B |
Elevance Health | 174.02B |
Pfizer | 59.38B |
Sanofi | 54.03B |
Medtronic | 33.00B |
Amgen | 32.53B |
Gilead Sciences | 28.30B |
Stryker | 21.97B |
BMY News
- 1 day ago - Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript) - Seeking Alpha
- 2 days ago - Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms - Business Wire
- 2 days ago - Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases - Benzinga
- 3 days ago - Bristol-Myers Squibb: Buy This Bargain Before It's Gone - Seeking Alpha
- 6 days ago - Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer - Business Wire
- 6 days ago - Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors - Business Wire
- 6 days ago - Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug - Reuters
- 8 days ago - Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock - Benzinga